Cargando…

Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer

The aim of this study is to evaluate the factors affecting the objective response rate (ORR) after neoadjuvant therapy of taxol plus platinum (TP) regimen combined with programmed cell death protein-1 (PD-1) inhibitors for esophageal cancer, and establish a predictive model for forecasting ORR. Acco...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Rulan, Yuan, Dawei, Mo, Caijing, Zhu, Kun, Dang, Chengxue, Zhang, Yong, Yin, Jianhao, Li, Kang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102326/
https://www.ncbi.nlm.nih.gov/pubmed/37055490
http://dx.doi.org/10.1038/s41598-023-33038-w
_version_ 1785025670500319232
author Ma, Rulan
Yuan, Dawei
Mo, Caijing
Zhu, Kun
Dang, Chengxue
Zhang, Yong
Yin, Jianhao
Li, Kang
author_facet Ma, Rulan
Yuan, Dawei
Mo, Caijing
Zhu, Kun
Dang, Chengxue
Zhang, Yong
Yin, Jianhao
Li, Kang
author_sort Ma, Rulan
collection PubMed
description The aim of this study is to evaluate the factors affecting the objective response rate (ORR) after neoadjuvant therapy of taxol plus platinum (TP) regimen combined with programmed cell death protein-1 (PD-1) inhibitors for esophageal cancer, and establish a predictive model for forecasting ORR. According to the inclusion and exclusion criteria, consecutive esophageal cancer patients who were treated in the First Affiliated Hospital of Xi’an Jiaotong University from January 2020 to February 2022 were enrolled in this study as a training cohort, while patients who were treated in the Shaanxi Provincial Cancer Hospital Affiliated to Medical College of Xi’an Jiaotong University from January 2020 to December 2021 were enrolled as a validation cohort. All patients were treated with resectable locally advanced esophageal cancer and received neoadjuvant chemotherapy combined with immunotherapy. The ORR was defined as the sum of complete pathological response, major pathological response and partial pathological response. Logistic regression analysis was performed to determine the factors that might be related to the ORR of the patients after neoadjuvant therapy. The nomogram based on the result of regression analysis was established and verified to predict the ORR. In this study, 42 patients were included as training cohort and 53 patients were included as validation cohort. Chi-square analysis showed that neutrophil, platelet, platelet-to-lymphocytes ratio (PLR), systemic immune-inflammation index (SII), D-dimer and carcinoembryonic antigen (CEA) between ORR group and non-ORR group were significantly different. Logistic regression analysis showed that aspartate aminotransferase (AST), D-dimer and CEA were independent predictors of ORR after neoadjuvant immunotherapy. Finally, a nomogram was established based on AST, D-dimer and CEA. Internal validation and external validation revealed that the nomogram had a good ability to predict ORR after neoadjuvant immunotherapy. In conclusion, AST, D-dimer and CEA were the independent predictors of ORR after neoadjuvant immunotherapy. The nomogram based on these three indicators showed a good predictive ability.
format Online
Article
Text
id pubmed-10102326
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101023262023-04-15 Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer Ma, Rulan Yuan, Dawei Mo, Caijing Zhu, Kun Dang, Chengxue Zhang, Yong Yin, Jianhao Li, Kang Sci Rep Article The aim of this study is to evaluate the factors affecting the objective response rate (ORR) after neoadjuvant therapy of taxol plus platinum (TP) regimen combined with programmed cell death protein-1 (PD-1) inhibitors for esophageal cancer, and establish a predictive model for forecasting ORR. According to the inclusion and exclusion criteria, consecutive esophageal cancer patients who were treated in the First Affiliated Hospital of Xi’an Jiaotong University from January 2020 to February 2022 were enrolled in this study as a training cohort, while patients who were treated in the Shaanxi Provincial Cancer Hospital Affiliated to Medical College of Xi’an Jiaotong University from January 2020 to December 2021 were enrolled as a validation cohort. All patients were treated with resectable locally advanced esophageal cancer and received neoadjuvant chemotherapy combined with immunotherapy. The ORR was defined as the sum of complete pathological response, major pathological response and partial pathological response. Logistic regression analysis was performed to determine the factors that might be related to the ORR of the patients after neoadjuvant therapy. The nomogram based on the result of regression analysis was established and verified to predict the ORR. In this study, 42 patients were included as training cohort and 53 patients were included as validation cohort. Chi-square analysis showed that neutrophil, platelet, platelet-to-lymphocytes ratio (PLR), systemic immune-inflammation index (SII), D-dimer and carcinoembryonic antigen (CEA) between ORR group and non-ORR group were significantly different. Logistic regression analysis showed that aspartate aminotransferase (AST), D-dimer and CEA were independent predictors of ORR after neoadjuvant immunotherapy. Finally, a nomogram was established based on AST, D-dimer and CEA. Internal validation and external validation revealed that the nomogram had a good ability to predict ORR after neoadjuvant immunotherapy. In conclusion, AST, D-dimer and CEA were the independent predictors of ORR after neoadjuvant immunotherapy. The nomogram based on these three indicators showed a good predictive ability. Nature Publishing Group UK 2023-04-13 /pmc/articles/PMC10102326/ /pubmed/37055490 http://dx.doi.org/10.1038/s41598-023-33038-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ma, Rulan
Yuan, Dawei
Mo, Caijing
Zhu, Kun
Dang, Chengxue
Zhang, Yong
Yin, Jianhao
Li, Kang
Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer
title Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer
title_full Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer
title_fullStr Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer
title_full_unstemmed Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer
title_short Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer
title_sort factors affecting the orr after neoadjuvant therapy of tp regimen combined with pd-1 inhibitors for esophageal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102326/
https://www.ncbi.nlm.nih.gov/pubmed/37055490
http://dx.doi.org/10.1038/s41598-023-33038-w
work_keys_str_mv AT marulan factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer
AT yuandawei factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer
AT mocaijing factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer
AT zhukun factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer
AT dangchengxue factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer
AT zhangyong factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer
AT yinjianhao factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer
AT likang factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer